Background Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic
lymphoma kinase (ALK), showed promising efficacy and tolerability in the single-arm phase …

Background Anaplastic lymphoma kinase-positive (ALK-positive) disease occurs in
approximately 5% of all patients with non-small-cell lung cancer, with a similar incidence …

Background Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has
shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive …

Abstract Objectives The J-ALEX study compared the efficacy and safety of alectinib with
crizotinib in Japanese patients with advanced ALK-positive non-small-cell lung cancer …

Background Alectinib—a highly selective, CNS-active, ALK inhibitor—showed promising
clinical activity in crizotinib-naive and crizotinib-resistant patients with ALK-rearranged (ALK …

Background This is the first trial to directly compare efficacy and safety of alectinib versus
standard chemotherapy in advanced/metastatic anaplastic lymphoma kinase (ALK)-positive …

Background The ALEX study demonstrated significantly improved progression-free survival
(PFS) with alectinib versus crizotinib in treatment-naive ALK-positive non-small-cell lung …

Purpose Alectinib is an anaplastic lymphoma kinase (ALK)–specific kinase inhibitor that
seems to be effective against non–small-cell lung cancer (NSCLC) with a variety of ALK …

Introduction Alectinib demonstrated clinical efficacy and an acceptable safety profile in two
phase II studies (NP28761 and NP28673). Here we report the pooled efficacy and safety …

9008 Background: ALC showed promising efficacy and tolerability in the phase I/II study (AF-
001JP). Here, we conducted the randomized open-label phase III trial (J-ALEX study …